BioCryst Pharmaceuticals
BCRX
116 hedge funds and large institutions have $380M invested in BioCryst Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 32 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 30
0% less call options, than puts
Call options by funds: $4.84M | Put options by funds: $4.86M
1.35% less ownership
Funds ownership: 92.18% → 90.83% (-1.4%)
13% less funds holding
Funds holding: 133 → 116 (-17)
47% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 32
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
54% less capital invested
Capital invested by funds: $827M → $380M (-$447M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$33.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.9M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$13.4M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$12M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$70.5M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$48.5M |
| 3 |
Jennison Associates
New York
|
-$25.2M |
| 4 |
Janus Henderson Group
London,
|
-$16M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$5.7M |
BCRX Hedge Fund Activity: Q2 2019 in Review
116 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2019, worth a combined $380M — down 54% from $827M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of BCRX and 17 opened new positions — a net loss of 15 holders — while 30 trimmed existing stakes and 44 added.
The largest buyer was Millennium Management, adding an estimated $33.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $70.5M sold.
- 116 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2019, down from 133 in Q1 2019.
- Funds reported $380M of BioCryst Pharmaceuticals stock for Q2 2019, down 54% quarter-over-quarter.
- 17 funds opened new BioCryst Pharmaceuticals positions in Q2 2019 and 32 closed out, a net change of -15 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2019 was Millennium Management, an estimated $33.3M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2019 was RA Capital Management, an estimated $70.5M sold.
Based on aggregated 13F filings for Q2 2019.